The regulation of the tyrosine phosphorylation levels of these proteins by PTP1B in acquired and intrinsic Herceptin-resistant cancer cells could suggest applications for PTP1B inhibitors in combination with tyrosine kinase inhibitors for the treatment of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.